MONICA CHEN to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications MONICA CHEN has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
0.831
-
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases. J Thorac Oncol. 2026 03; 21(3):103505.
Score: 0.551
-
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases. J Immunother Cancer. 2026 May 04; 14(5).
Score: 0.143
-
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study. Lancet Oncol. 2025 Oct; 26(10):1357-1369.
Score: 0.137